دورية أكاديمية
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
| العنوان: | Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study |
|---|---|
| المؤلفون: | Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, for the Italian Migraine Registry study group |
| المصدر: | Neurology and Therapy, Vol 13, Iss 3, Pp 611-624 (2024) |
| بيانات النشر: | Adis, Springer Healthcare, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Neurology. Diseases of the nervous system |
| مصطلحات موضوعية: | Fremanezumab, Migraine treatment, CGRP monoclonal antibody, Real-world, Long-term treatment, Psychiatric comorbidities, Neurology. Diseases of the nervous system, RC346-429 |
| الوصف: | Abstract Introduction Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and 3 treatment failures and various comorbidities. Methods A 48-week, prospective, multicenter (n = 26), cohort study assessed fremanezumab’s effectiveness, safety, and tolerability in consecutive adults with HFEM or CM with > 3 treatment failures. Primary endpoint was variation from baseline in monthly migraine days (MMD) in HFEM and monthly headache days (MHD) in CM at weeks 45–48. Secondary endpoints were changes in monthly analgesic medications, Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), and the Migraine Disability Assessment Scale (MIDAS) scores and ≥ 50%, ≥ 75%, and 100% responder rates. Results Of 533 participants who had received ≥ 1 fremanezumab dose, 130 were treated for ≥ 48 weeks and considered for effectiveness analysis. No participant missed any treatment dosage every other consecutive month during the 12-month period. Primary endpoint: fremanezumab significantly (p 3) therapeutic failures, even in the presence of concomitant medication overuse, psychiatric comorbidities, or both. The effectiveness-to-tolerability ratio appears to be better in RWE than in RCTs. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2193-8253 2193-6536 |
| العلاقة: | https://doaj.org/toc/2193-8253Test; https://doaj.org/toc/2193-6536Test |
| DOI: | 10.1007/s40120-024-00591-z |
| الوصول الحر: | https://doaj.org/article/466e8ed5e5ca4896b88d65d5aed29347Test |
| رقم الانضمام: | edsdoj.466e8ed5e5ca4896b88d65d5aed29347 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 21938253 21936536 |
|---|---|
| DOI: | 10.1007/s40120-024-00591-z |